Table 2.
Baseline patient characteristic: validation cohort
| Variable | M0 n (%) | HEP n (%) | PER n (%) | HEP/PER n (%) | p-value |
|---|---|---|---|---|---|
| Patients | 47 | 51 | 44 | 28 | |
| Medium age (y) | 66 | 65 | 67 | 61 | 0.55 |
| Sex | |||||
| Female | 20 (44.0) | 24 (47.0) | 23 (52.5) | 13 (46.0) | 0.36 |
| Male | 27 (56.0) | 27 (53.0) | 21 (47.5) | 15 (54.0) | |
| Location of PT | |||||
| Right colon | 15 (27.8) | 15 (28.9) | 17 (38.5) | 9 (31.6) | 0.80 |
| Left colon | 32 (72.2) | 36 (71.1) | 27 (61.5) | 17 (68.4) | |
| UICC | |||||
| I | 17 (36.0) | 1 (2.9) | 0 (0.0) | 0 (0.0) | 0.00011 |
| II | 11 (23.5) | 3 (5.9) | 4 (9.0) | 2 (7.1) | |
| III | 19 (40.5) | 6 (1.8) | 14 (31.0) | 4 (14.3) | |
| IV | 0 | 41 (89.4) | 26 (60.0) | 22 (78.6) | |
| Grading | |||||
| Low grade | 29 (61.7) | 29 (56.9) | 22 (50.0) | 17 (60.8) | 0.70 |
| High grade | 18 (38.3) | 22 (44.1) | 22 (50.0) | 11 (39.2) | |
| Time of liver metastases | |||||
| Synchron | n.a. | 41 (89.4) | n.a. | 22 (78.6) | 0.5 |
| Metachron | n.a. | 10 (10.6) | n.a. | 6 (22.4) | |
| Tumor perforation | |||||
| Yes | 0 (0.0) | 3 (5.9) | 4 (9.1) | 10 (35.7) | 0.0002 |
| No | 47 (100) | 48 (94.1) | 40 (90.9) | 18 (64.3) | |
UICC union for international cancer control, T tumor size, N lymph node status, n.a. not applicable